The latest price target for Lexicon Pharmaceuticals (NASDAQ:LXRX) was reported by Piper Sandler on March 7, 2025. The analyst firm set a price target for $6.00 expecting LXRX to rise to within 12 months (a possible 1567.59% upside). 35 analyst firms have reported ratings in the last year.

The latest analyst rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) was provided by Piper Sandler, and Lexicon Pharmaceuticals maintained their overweight rating.

There is no last upgrade for Lexicon Pharmaceuticals

The last downgrade for Lexicon Pharmaceuticals Inc happened on March 4, 2025 when Leerink Partners changed their price target from N/A to $1 for Lexicon Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lexicon Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lexicon Pharmaceuticals was filed on March 7, 2025 so you should expect the next rating to be made available sometime around March 7, 2026.

While ratings are subjective and will change, the latest Lexicon Pharmaceuticals (LXRX) rating was a maintained with a price target of $10.00 to $6.00. The current price Lexicon Pharmaceuticals (LXRX) is trading at is $0.36, which is out of the analyst’s predicted range.